New Delhi, June 13 :    New Delhi, June 13:  Glaxo India Ltd is going to launch Twinrix-a vaccine for both Hepatitis A and B-in the domestic market by the end of this year. Twinrix is available in the western markets for the last three years. Kalyan Sundaram, director, pharmaceuticals, told The Telegraph that Glaxo has already got the necessary approvals from the regulatory authorities to launch the product. Stating that hepatitis is widely prevalent in India, Sundaram said the unique thing about Twinrix is that it is a combined vaccination for both Hepatitis A and B. In the Indian market, most vaccines are for Hepatitis B only, he said. Glaxo is also planning to launch an anti-diarrhoea oral treatment next year, subject to necessary approvals. Though the product is available in international markets, the company refused to divulge the brandname of the product as it has filed for legal approvals in the country. Both Twinrix and the anti-diarrhoea drug will be imported by Glaxo India from its parent company. Today, Glaxo India launched its oral smoking cessation product Zyban in north India. Zyban will be available in Calcutta next week. It was first launched in Mumbai on May 31. The nationwide launch will be over in three months, Kalyan Sundaram said.